+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Vulval Atrophy"

Atrophic Vaginitis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Atrophic Vaginitis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Atrophic Vaginitis - Pipeline Insight, 2021 - Product Thumbnail Image

Atrophic Vaginitis - Pipeline Insight, 2021

  • Clinical Trials
  • January 2021
  • 60 Pages
  • Global
From
From
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018 - Product Thumbnail Image

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018

  • Drug Pipelines
  • June 2018
  • 37 Pages
  • Global
From
From
Atrophic Vaginitis Disease - Global Clinical Trials Review, H1, 2021 - Product Thumbnail Image

Atrophic Vaginitis Disease - Global Clinical Trials Review, H1, 2021

  • Clinical Trials
  • February 2021
  • 152 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Vulval Atrophy is a condition that affects women's health, characterized by thinning and inflammation of the vulval skin. It is caused by a decrease in estrogen levels, which can occur naturally during menopause or as a result of certain medical treatments. Symptoms of Vulval Atrophy include itching, burning, and pain during intercourse. Treatment options include topical creams, oral medications, and laser therapy. The Vulval Atrophy market is an important part of Women's Health, as it provides treatments for a condition that can have a significant impact on quality of life. Companies in this market are focused on developing treatments that are effective, safe, and easy to use. Examples of companies in this market include Allergan, Pfizer, and Merck. Show Less Read more